🕒 Last update: loading…

Stock PMV Pharmaceuticals, Inc. PMVP

PMV Pharmaceuticals, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2020 → 2021: -62.45%

Price change 2021 → 2022: -62.34%

Price change 2022 → 2023: -64.37%

Price change 2023 → 2024: -51.29%

Price change 2024 → 2025: -17.22%

Price change 2025 → 2026: -11.20%

Price change 2026 (year to date): -9.76%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.01

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -1.20

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 38.33% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
PMV Pharmaceuticals, Inc.–0.01–🔒
Klea Holding18.10.20+5.2 %–
Euroapi S.A.–0.08−1.3 %–
DocCheck AG11.30.10+8.9 %–
Coherus Oncology, Inc.–0.66+26.9 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 25/09/2020
ISIN code
US69353Y1038
Workforce
47
full-time employees
Chief executive
David H. Mack

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about PMV Pharmaceuticals, Inc.

What is the PMV Pharmaceuticals, Inc. share price?

Latest recorded price: 1.27 USD on 13/11/2026, for a market cap of 67.7 m USD.

Is PMV Pharmaceuticals, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US69353Y1038).

How many employees does PMV Pharmaceuticals, Inc. have?

47 full-time employees according to the latest published profile.

Who runs PMV Pharmaceuticals, Inc.?

David H. Mack is the company's chief executive.

07

Similar stocks